A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cacers Harboring HER2 Aberration in Japan (HER2-CS STUDY).

CONCLUSIONS: This prospective large-scale cohort study is the first to show comprehensively the frequency and clinical demographic characteristics of those with HER2-positive advanced lung tumors in detail, providing critical historical data for future drug development against HER2-positive NSCLC. Future treatment strategies would be developed stratified according to the types of HER2 aberrations. TRIAL REGISTRY: UMIN Registration No. 000017003; URL: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019691. PMID: 31072612 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31072612?dopt=Abstract

Source: Chest - May 5, 2019 Category: Respiratory Medicine Authors: Ninomiya K, Hata T, Yoshioka H, Ohashi K, Bessho A, Hosokawa S, Ishikawa N, Yamasaki M, Shibayama T, Aoe K, Kozuki T, Harita S, Ueda Y, Murakami T, Fujimoto N, Yanai H, Toyooka S, Takata M, Hotta K, Kiura K, HER2-CS Network Tags: Chest Source Type: research